Alnylam grants Bioneer license to Kreutzer-Limmer patents for RNai research

By Elaine Rigoli

Tampa, Fla., May 24 - Alnylam Pharmaceuticals, Inc. has granted Bioneer, Inc. a non-exclusive license to provide RNA interference, or RNAi, research products under the Kreutzer-Limmer patent family.

This patent family, owned exclusively by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells, according to a news release.

Alnylam's intellectual property estate includes certain "fundamental" patents and patent applications that claim the broad structural and functional properties of synthetic RNAi products.

Alnylam, based in Cambridge, Mass., is a biopharmaceutical company developing novel therapeutics based on RNAi.

Based in Daejeon, South Korea, Bioneer is a supplier of synthetic oligonucleotides.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.